Ikena Oncology, INC 8-K filings

ImageneBio announced its second quarter 2026 financial results, detailing progress in its Phase 2b ADAPTIVE trial for olevaprubart and a robust cash position extending into early 2028.

ImageneBio, Inc. announced the appointment of Yanina Grant-Huerta as Chief Financial Officer and the transition of Chief Medical Officer Benjamin Porter-Brown to a consulting role.

ImageneBio, Inc. announced the resignation of Robert Lally, Senior Vice President of Finance and Operations, effective July 22, 2026.

ImageneBio, Inc. announced the approval of an amendment to its 2025 Equity Incentive Plan, increasing authorized shares and including convertible securities in reserve calculations.

ImageneBio, Inc. announced a $30 million private placement of pre-funded warrants to institutional and accredited investors to fund late-phase development and expand indications for its product candidates.

ImageneBio, Inc. announced the mutual separation of its Principal Accounting Officer, Erin Butler, and the appointment of Bob Lally to the role, effective March 20, 2026.

IMAGENEBIO, INC. announced the resignation of its Chief Medical Officer, Dr. Yufang Lu, effective December 31, 2025, with a search for a replacement initiated.

ImageneBio, Inc. updated its corporate presentation, showcasing IMG-007's promising Phase 1b/2a results in atopic dermatitis and alopecia areata, and outlining its Phase 2b ADAPTIVE study.

ImageneBio announced its third quarter 2025 financial results, reporting a significant increase in net loss alongside a strong cash position and strategic updates for its lead therapeutic candidate, IMG-007.

ImageneBio, Inc. announced the expansion of its Board of Directors and the appointment of Joseph P. Slattery, who will also chair the Audit Committee.

Imagenebio, Inc. announced it will not renew its full transition services agreement with Miragene Inc. but will extend critical chemistry, manufacturing, and controls support for six months.

ImageneBio, Inc. announced that CEO Kristin Yarema, Ph.D., has been appointed as the interim principal financial officer, effective immediately.

IMAGENEBIO, INC. announced the resignation of its Chief Financial Officer, Jotin Marango, M.D., Ph.D., effective October 20, 2025.

ImageneBio, formerly Ikena Oncology, Inc., completed its merger with Inmagene Biopharmaceuticals, securing $75 million in financing and focusing its pipeline on the lead asset IMG-007.

ImageneBio, Inc. announced the dismissal of Ernst & Young LLP as its independent auditor and the appointment of PricewaterhouseCoopers LLP, effective August 2, 2025.

ImageneBio, Inc. has adopted its 2025 Inducement Plan, reserving 589,585 shares of common stock for equity awards to new employees and directors, aiming to attract and retain talent.

ImageneBio, Inc. (formerly Ikena Oncology, Inc.) has successfully completed its merger with Inmagene Biopharmaceuticals, raising $75 million in a private placement and divesting non-core assets to concentrate on its lead immunology and inflammatory drug candidate, IMG-007.

Ikena Oncology and Inmagene Biopharmaceuticals have completed their merger, forming ImageneBio, Inc., which also secured a $75 million private placement and will focus on advancing its lead asset, IMG-007, for immunological and inflammatory diseases.

Ikena Oncology, Inc. will effect a 1-for-12 reverse stock split, change its name to ImageneBio, Inc., and trade under the new ticker symbol IMA on Nasdaq, effective July 28, 2025, in anticipation of a proposed merger.

Ikena Oncology's board has approved a one-time special dividend of contingent value rights (CVRs) for its stockholders, effective July 24, 2025, in connection with its pending merger with Inmagene Biopharmaceuticals.

Ikena Oncology, Inc. has amended its employment agreement with Dr. Jotin Marango, providing enhanced severance benefits tied to the company's contemplated merger with Inmagene Biopharmaceutics.

Ikena Oncology, Inc. stockholders have overwhelmingly approved all key proposals, including the merger with Inmagene Biopharmaceuticals and a 1-for-12 reverse stock split, setting the stage for the combined entity, ImageneBio, Inc., to trade on Nasdaq under the ticker IMA.

Ikena Oncology announced that leading independent proxy advisory firms, Institutional Shareholder Services and Glass, Lewis & Co., recommend stockholders vote FOR the proposed merger with Inmagene Biopharmaceuticals.

Inmagene Biopharmaceuticals, the company set to merge with Ikena Oncology, announced the successful dosing of the first patient in its global Phase 2b ADAPTIVE trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline data expected in late 2026.

Ikena Oncology and Inmagene Biopharmaceuticals have agreed to merge, with a focus on developing Inmagenes IMG-007, supported by a $75 million private placement.

Ikena Oncology has appointed Jotin Marango, currently CFO, as Chief Operating Officer, effective July 15, 2024, with a salary increase and stock options.

Ikena Oncology held its annual meeting on June 7, 2024, where stockholders elected two Class III directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Ikena Oncology is discontinuing the development of IK-930, reducing its workforce by 53%, and exploring strategic options while continuing the clinical development of IK-595.

Ikena Oncology has announced the resignation of its Chief Medical Officer, Dr. Sergio Santillana, and the appointment of Dr. Caroline Germa as his successor, effective February 29, 2024.

Ikena Oncology announces a strategic workforce reduction and reallocation of resources to focus on its clinical-stage oncology programs, extending its cash runway into the second half of 2026.